Recent News

• 02.11.2026 - Outlook Therapeutics Submits Type A Meeting Request to FDA Following Complete Response Letter
• 01.06.2026 - Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development
• 12.31.2025 - Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
• 12.26.2025 - Outlook Therapeutics Announces New Employment Inducement Grants
• 12.19.2025 - Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
• 11.24.2025 - Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
• 11.13.2025 - Outlook Therapeutics Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
• 11.03.2025 - Outlook Therapeutics Re-Submits Biologics License Application for ONS-5010

Recent Filings

• 02.11.2026 - EX-99.1 EX-99.1
• 02.11.2026 - 8-K Current report
• 02.05.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.26.2026 - DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
• 01.26.2026 - ARS Annual Report to Security Holders
• 01.26.2026 - DEF 14A Other definitive proxy statements
• 01.02.2026 - EX-99.1 EX-99.1
• 01.02.2026 - 8-K Current report
• 12.19.2025 - 8-K Current report
• 12.19.2025 - EX-99.1 EX-99.1